A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.
Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how
long the tumor shrinkage can be maintained in patients with breast cancer after having had
taxol or taxotere. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be
off drug for 7 days before starting the next cycle of drug.